Complex | |
AACDB_ID: | 6552 |
PDBID: | 7SHY |
Chains: | EF_B |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 3.00 |
Reference: | 10.1038/s41467-021-27397-z |
Antibody | |
Antibody: | Omalizumab Fv |
Antibody mutation: | No |
INN (Clinical Trial): | Omalizumab(Approved) |
Antigen | |
Antigen: | IgE Fc |
Antigen mutation: | No |
Durg Target: | P01854 |
Antibody
Heavy Chain: E
Mutation: NULL
>7SHY_E|Chain A[auth C], B[auth E], C[auth I], J[auth K]|Omalizumab VH|Homo sapiens (9606) SEVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS |
Light Chain: F
Mutation: NULL
>7SHY_F|Chain D, E[auth F], F[auth J], K[auth L]|Omalizumab VL|Homo sapiens (9606) GSDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKGGSENLYFQGGSGHHHHHHHH |
Antigen
Chain: B
Mutation: NULL
>7SHY_B|Chain G[auth A], H[auth B], I[auth G], L[auth H]|IgE Fc|Homo sapiens (9606) APMAEGGGQNHHHHHHHHGGENLYFQGGSCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
E: TYR27 SER31 GLY32 TYR33 TYR54 SER100 HIS101 TYR102 PHE103 TRP106 F: ASP32 GLY33 ASP34 TYR36 TYR53 TYR57 SER71 B: ASN371 THR373 TRP374 SER375 ARG376 ALA377 SER378 GLY379 LYS380 PRO381 GLU414 GLN417 ARG419 THR421 PRO426 ARG427 ALA428 MET430 SER432 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)